CJC-1295 / Ipamorelin Benefits: What the Studies Measured

By DoseGauge Editorial · Updated 2026-06-13 · 7 min read

What the studies on these peptides actually measured is an increase in the body's own growth hormone and IGF-1 secretion: CJC-1295 produced prolonged elevation of growth hormone and IGF-1 in healthy adults (Teichman et al., 2006), and Ipamorelin selectively stimulated growth hormone release in the preclinical work that introduced it (Raun et al., 1998). That is a pharmacology finding. It is not proof that the blend builds muscle, reduces fat, or reverses aging in humans. Neither peptide is approved by the FDA for human use, and rigorous human trials measuring those outcomes for this blend are lacking. This page reports what the research measured. It does not promise a result, and it is informational and educational only, not medical advice.

What the studies measured

The studies most often cited for these peptides measured one thing: an effect on the body's own growth hormone and, downstream, IGF-1. It helps to read them for exactly what they reported, and nothing more.

In healthy adults, CJC-1295 produced prolonged, dose-dependent increases in growth hormone and IGF-1 (Teichman et al., 2006). The study tracked plasma hormone concentrations and the pharmacokinetics of the peptide itself, reporting that growth hormone rose by several-fold for multiple days and IGF-1 rose for roughly a week or more after dosing. That is a measurement of hormone secretion and drug behavior. It was not a trial of muscle, fat, strength, or aging, and it did not report any body-composition outcome.

Ipamorelin was introduced as the first selective growth hormone secretagogue, with a selectivity for growth hormone release similar to that of GHRH (Raun et al., 1998). In that work, Ipamorelin stimulated growth hormone release while, unlike earlier non-selective secretagogues, not raising ACTH or cortisol. Two things about this study matter for setting expectations. First, it was preclinical: the experiments were in cultured pituitary cells, rats, and swine, not a human outcome trial. Second, like the CJC-1295 study, it measured hormone release, not body composition. Ipamorelin is also catalogued as a distinct chemical compound (Ipamorelin, PubChem CID 9831659).

So the honest summary of the evidence is narrow and specific. These peptides have been shown to raise growth hormone and IGF-1, one in healthy adults and one in animals. That is the measured finding. Everything beyond it is inference.

What "raises GH and IGF-1" does and does not mean

It is tempting to treat a hormone-secretion finding as if it were an outcome. It is not. There is a real gap between "this peptide raised growth hormone and IGF-1 in a study" and "this peptide will build your muscle or burn your fat," and that gap is where most of the marketing lives.

Raising a signaling hormone is a mechanism. Whether that mechanism translates into a clinical outcome, like measurable muscle gain, fat loss, faster recovery, better sleep, or any anti-aging effect, is a separate question that has to be answered by trials designed to measure those outcomes directly, in people, with controls. For this blend, those trials do not exist. The studies cited above measured hormone levels and drug behavior; they did not measure body composition, and a body-composition result cannot be read out of a hormone-secretion result.

This distinction is not a technicality. Plenty of compounds move a biomarker in the expected direction and still fail to produce the downstream benefit when it is actually measured, and the size of any hormone change does not tell you the size of a real-world effect. So the accurate reading of CJC-1295 / Ipamorelin is that the research supports a pharmacology claim, namely that these peptides raise growth hormone and IGF-1, and the research does not support a clinical claim about what that does to a human body.

What the evidence does not show

Being precise about the gaps is the whole point of this page. The following are commonly marketed benefits of CJC-1295 / Ipamorelin, and for each one the evidence base is the same: there is no rigorous human trial of this blend demonstrating it.

There is no rigorous human trial showing the blend builds muscle. There is no rigorous human trial showing it reduces body fat. There is no rigorous human trial showing it reverses or slows aging. There is no rigorous human trial showing it improves recovery, and none showing it improves sleep. The hormone-secretion findings above are real, but they are not a substitute for any of these outcomes, and they should not be presented as one.

In short, the commonly marketed claims outrun the evidence. The research measured growth hormone and IGF-1; the marketing sells muscle, fat loss, recovery, sleep, and youth. Those are not the same thing, and neither CJC-1295 nor Ipamorelin is FDA-approved for human use, so there is no agency-reviewed efficacy record to fall back on either. Anyone presenting these body-composition or anti-aging outcomes as established is presenting something the published evidence does not support.

A note on expectations

A mechanism finding is a reason for researchers to keep studying a compound. It is not a promise to an individual. The fact that CJC-1295 raised growth hormone in a small study, or that Ipamorelin raised it in animals, tells you what the peptides did under those conditions; it does not tell you what will happen to a specific person, at a specific dose, over time, because that has not been studied in the trials it would take to know.

Whether any peptide is appropriate for a particular person is a clinical question, and the right place to take it is a licensed clinician who knows your situation. DoseGauge does not assess benefit and does not recommend these peptides for any purpose. The calculator on this site recommends no dose; it performs reconstitution and syringe-unit math on the numbers you enter and makes no claim about whether the compound produces any effect.

For the safety picture, see side effects. For background on the compounds themselves, see what it is.

Frequently asked questions

What are the benefits of CJC-1295 / Ipamorelin?

What the studies measured is an increase in the body's own growth hormone and IGF-1: CJC-1295 raised both in healthy adults (Teichman et al., 2006), and Ipamorelin selectively stimulated growth hormone release in preclinical work (Raun et al., 1998). That is a pharmacology finding, not a proven benefit. There are no rigorous human trials showing the blend builds muscle, reduces fat, improves recovery or sleep, or reverses aging, and neither peptide is FDA-approved for human use. This page reports the evidence and does not claim a benefit.

Does CJC-1295 / Ipamorelin build muscle?

The studies measured raised growth hormone and IGF-1, not muscle gain in humans. A hormone-secretion finding is not the same as a body-composition outcome, and muscle gain from this blend has not been demonstrated in a rigorous human trial. It is also not FDA-approved for human use. So the accurate answer is that muscle gain is not an established outcome for CJC-1295 / Ipamorelin, regardless of how it is marketed.

How long until CJC-1295 / Ipamorelin works?

There is no reliable answer, because "works" implies an established human outcome, and none has been demonstrated for this blend. The cited studies measured how long the hormone effect lasted, with CJC-1295 elevating growth hormone and IGF-1 for several days after dosing in healthy adults (Teichman et al., 2006), but that describes the duration of a hormone change, not a timeline to muscle, fat loss, or any other benefit. No such timeline is established.

Is CJC-1295 / Ipamorelin proven to work?

No, not for the outcomes it is usually sold for. The research proves a narrow pharmacology point, that these peptides raise growth hormone and IGF-1, one in healthy adults and one in animals. It does not prove the blend builds muscle, reduces fat, or reverses aging in humans, because rigorous human trials measuring those outcomes do not exist, and neither peptide is FDA-approved. The commonly marketed claims outrun the evidence.

Informational and educational only. Not medical advice. DoseGauge computes from the values you enter and does not recommend a dose. Talk to a licensed clinician before using any peptide or GLP-1 medication.